检索结果-南通市图书馆

Impact of Combination Use of 0.004% Travoprost and 2% Pilocarpine on Matrix Metalloproteinases Synthesized by Rabbit Ciliary Muscle:a Pilot Study

引用

Chinese Medical Sciences Journal 2013年第4期28卷 229-232页

作者： Shun-hua Zhang Jia-liang Zhao Department of Ophthalmology Peking Union Medical College HospitalChinese Academy of Medical Sciences & Peking Union Medical College

Objective To explore the impact of combination use of prostaglandin analogue and cholinergic agonists on main matrix metalloproteinases(MMPs)synthesized by albino rabbit ciliary *** Normal adult albino rabbits were divided into the control group,2%pilocarpine group,0.004%travoprost group and travoprost plus pilocarpine *** rabbits in the control group were executed after treated with normal saline for one *** rabbits were separately executed on the 7th,14th and 24th day of the treatment in each drug treated *** each subgroup ciliary muscle band of 4 eyes was taken and made into *** MMPs activities of 10 subgroups were assayed by ***’intensity which represents the activity of MMPs was measured by the UltraViolet Illumination *** A bright band of MMP-1/2 was showed on each lane at the position corresponding to the molecular weight of 62 kD in the ciliary smooth muscles *** ion Zn and Ca was displaced by MMPs inhibitor EDTA,this bright band *** with the control group,MMP1/2 activity increased by 4.0%,4.1%and 14.0%after 7,14 and 24 days of pilocarpine *** data was23.2%,61.7%and 111.5%in the travoprost group and 49.3%,68.0%and 88.4%in the travoprost plus pilocarpine *** Pilocarpine has little effect on activity of MMP1/*** can increase activity of MMP1/2 *** of MMP1/2 is rapidly increased by pilocarpine combined with travoprost,but shows small change with the prolonged treatment.

关键词： matrix metalloproteinases prostaglandin analogue pilocarpine

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Intraocular pressure lowering efficacy and safety of travoprost 0.004 % as a replacement therapy in patients with open angle glaucoma or ocular hypertension

引用

Chinese Medical Journal 2010年第11期123卷 1417-1421页

作者： GE Jian SUN Xing-huai WANG Ning-li ZHAO Jia-liang WU Ling-ling CHEN Xiao-ming WANG Zhi-xin Benny Li Zhongshan Ophtllalmic Center State Key Laboratory ofOphthalmology Sun Yat-sen University Guangzhou Guangdong510060 China Department of Ophtthalmology Eye Ear Nose and Throat HospitalSchool of Medicine Fudan University Shanghai 200031 China Beijing Tongren Eye Center Beijing Tongren Hospital CapitalMedical University Beijing Ophthalmology & Visual SciencesKey Laboratory Beijing 100730 China Department of Ophthalmology Peking Union Medical CollegeHospital Chinese Academy of Medical Sciences Beijing 100730China Peking University Eye Center Peking University Third HospitalBeijing 100191 China Depal~ment of Ophthalmology West China Hospital SichuanUniversity Chengdu Sichuan 610041 China Alcon Research Ltd. 6201 South Freeway Fort Worth Texas76134 USA

Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma （OAG） or ocular hypertension （OH）. The aim of this study was to evaluate the intraocular pressure （lOP） lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients. Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy （due to either inadequate efficacy or safety issues） as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. lOP measurements were performed at the same time of day at the follow-up visits. Results For patients transitioned to travoprost, mean lOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were： latanoprost, （4.3±4.6） mmHg; β-blocker, （6.3±4.0） mmHg; α-agonist, （7.5±4.3） mmHg; topical carbonic anhydrase inhibitors, （8.0±4.9） mmHg. All mean lOP changes from baseline were statistically significant （P 〈0.001）. No treatment-related serious adverse events were reported in this study. Conclusions In patients treated with other hypotensive medications or untreated, the lOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate lOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.

关键词： travoprost prostaglandin analogue intraocular pressure glaucoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：